Actively Recruiting
Tissue Study in Patients Undergoing CAR-T Cell Therapy (CAR_21_01)
Led by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Updated on 2024-12-27
150
Participants Needed
1
Research Sites
254 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The "CAR-T" immunotherapy ("Chimeric Antigen Receptor T cell therapies") is a therapy based on T cells expressing a chemical receptor for a specific antigen indicated for patients with some types of oncohematological pathologies that have not responded to other forms treatment, such as: relapsed or refractory non-Hodgkin's lymphomas, including diffuse large B-cell lymphoma, primary B-cell mediastinal lymphoma, transformed follicular lymphoma, mantle cell lymphoma, acute lymphoblastic leukemia, in children and young adults (\<26 years) and multiple myeloma. This therapy is an absolutely innovative approach which consists of a personalized live cell immunotherapy that modifies the immune system of the recipient patient to make it able to recognize and eradicate the neoplastic cells expressing the antigen towards which the cells have been engineered. This approach has several biological advantages: 1. to supply the patient with "reprogrammed T cells" with a new and specific activation mechanism; 2. overcoming immune tolerance towards cancer cells; 3. bypassing HLA-mediated antigen recognition restriction mechanisms;
CONDITIONS
Official Title
Tissue Study in Patients Undergoing CAR-T Cell Therapy (CAR_21_01)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 years or older
- Patients with hematological disease scheduled for CAR-T therapy at the Advanced Cell Therapy Program, IRCCS University Hospital of Bologna
- Patients who have signed informed consent to participate in the study
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
IRCC, University Hospital of Bologna
Bologna, Italy, Italy, 40138
Actively Recruiting
Research Team
F
Franscesca Bonifazi, MD
CONTACT
E
Enrica Tomassini, DM
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here